Search results for "Cutaneous"

showing 10 items of 1022 documents

Wistar rat skin as surrogate for human skin in nortriptyline hydrochloride patch studies

2009

Six different matrices were prepared containing nortriptyline hydrochloride (NTH) with hydroxypropyl-methyl-cellulose as polymer. A mixture of transdermal enhancers was included as part of the vehicle. Diffusion studies were carried out through Wistar rat full thickness skin using Franz cells. They were compared with previously determined human heat separated epidermis in order to test if this animal can be used as model for in vivo assays. A linear correlation was obtained between NTH diffusion coefficients through both skin types (r2=0.996).

MaleSkin AbsorptionPharmaceutical ScienceHuman skinNortriptylineIn Vitro TechniquesPharmacologyAdministration CutaneousDosage formIn vivoFull thickness skinAnimalsMedicineRats WistarSkinTransdermalChromatographyintegumentary systemEpidermis (botany)business.industryRatsNortriptyline HydrochlorideModels AnimalNortriptylinebusinessmedicine.drugInternational Journal of Pharmaceutics
researchProduct

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

2017

This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease.The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months. Secondary endpoints included the assessment of motor symptoms by Unified Parkinson's Disease Rating Scale III scores.Data from 378 patients (mean age: 70.2 years; 56.9% male) with Parkinson's disease receiving rotigotine from were collected. Mean disease…

MaleSleep Wake Disordersmedicine.medical_specialtyParkinson's diseaseTetrahydronaphthalenesThiophenesDiseaseAdministration CutaneousMotor symptoms03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesProduct Surveillance PostmarketingmedicineHumans030212 general & internal medicineAgedRetrospective StudiesTransdermalAged 80 and overbusiness.industryGeneral NeuroscienceParkinson DiseaseRotigotineGeneral MedicineUrination Disordersmedicine.diseaseClinical PracticeTreatment OutcomeSpainDopamine AgonistsPhysical therapyNon motorFemaleObservational studyCognition Disordersbusiness030217 neurology & neurosurgerymedicine.drugInternational Journal of Neuroscience
researchProduct

Controlled Iontophoretic Delivery in Vitro and in Vivo of ARN14140—A Multitarget Compound for Alzheimer’s Disease

2019

ARN14140 is a galantamine-memantine conjugate that acts upon both cholinergic and glutamatergic pathways for better management of Alzheimer's disease. Poor oral bioavailability and pharmacokinetics meant that earlier preclinical in vivo studies employed intracerebroventricular injection to administer ARN14140 directly to the brain. The aim of the present study was to evaluate the feasibility of using constant current transdermal iontophoresis for the noninvasive systemic delivery of ARN14140 and to quantify the amounts present in the blood and the brain. Preliminary experiments in vitro were performed using porcine skin and validated with human skin. Cumulative ARN14140 permeation across th…

MaleSwineSkin Absorptionbrain deliveryBiological AvailabilityPharmaceutical ScienceHuman skin02 engineering and technologyPharmacologyAdministration Cutaneous030226 pharmacology & pharmacyPermeability03 medical and health sciences0302 clinical medicineDrug StabilityPharmacokineticsIn vivoDrug DiscoveryARN14140AnimalsBrain/metabolismHumansSkin/metabolismMedicineTissue DistributionRats WistarNootropic Agents/administration & dosage/pharmacokineticsTransdermalddc:615galantamine-memantine conjugateAlzheimer Disease/drug therapyIontophoresisbusiness.industryGalantamine/administration & dosage/pharmacokineticsiontophoresiIontophoresisMemantine/administration & dosage/pharmacokinetics021001 nanoscience & nanotechnologyIn vitroRatsBioavailabilityHeterocyclic Compounds 4 or More Rings/administration & dosage/pharmacologytransdermalFeasibility StudiesMolecular MedicineCholinergic0210 nano-technologybusinessMolecular Pharmaceutics
researchProduct

Long-term follow-up after drug eluting stent implantation in left main trifurcations

2009

Aims: Trifurcation lesions, which are mostly observed in distal left main (LM), represent a technical challenge for interventional cardiologists. We sought to determine the feasibility and long-term clinical outcome of drug eluting stent (DES) implantation in patients with LM coronary trifurcation lesions. Methods and results: All patients with clinically significant de novo LM trifurcation lesions, who refused coronary artery bypass surgery and were considered eligible for percutaneous coronary intervention (PCI), were consecutively enrolled in this study from November 2005 to February 2007. Eleven patients (65±9 years, 91% men) met all the inclusion criteria and underwent LM trifurcation …

MaleTarget lesionmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentTrifurcation lesions.Coronary DiseaseCoronary AngiographyCoronary artery bypass surgeryClinical endpointStentHumansMedicineMyocardial infarctionAgedSirolimusbusiness.industryAngioplastyStentPercutaneous coronary interventionDrug-Eluting StentsEquipment DesignMiddle Agedmedicine.diseaseCoronary VesselsDESTubulin ModulatorsSurgeryDrug-eluting stentConventional PCIFemaleRadiologyCardiology and Cardiovascular MedicinebusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian …

2022

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition…

MaleTicagrelorAspirinMyocardial InfarctionAnticoagulantsHemorrhageFactor XIaPercutaneous Coronary InterventionTreatment OutcomeDouble-Blind MethodPhysiology (medical)HumansFemale03.02. Klinikai orvostanAcute Coronary SyndromeCardiology and Cardiovascular MedicinePrasugrel HydrochloridePlatelet Aggregation InhibitorsAgedCirculation
researchProduct

Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute co…

2020

Abstract Aims In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome. Methods and results The primary endpoint of the study was the change in endothelium-dependent flow-mediated dilation (FMD) following stenting. A total of 90 patients (age 62 ± 9 years, 81 males, 22 diabetics, 49 non-ST elevation myocardial infarctions) were enrolled. There were no significant differences among groups in any clinical parameter. Acutely before stenting, all three drugs improved FMD without differences between groups (P = 0.73). Stenting blunted FMD in the cl…

MaleTicagrelormedicine.medical_specialtyAcute coronary syndromeAdenosinePrasugrelmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineClinical endpointHumansMedicineEndotheliumcardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryStentMiddle Agedmedicine.diseaseClopidogrelCoronary VesselsThrombosisConfidence intervalClopidogrelTreatment OutcomePurinergic P2Y Receptor AntagonistsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPrasugrel HydrochlorideTicagrelorPlatelet Aggregation Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?

2016

MaleTicagrelormedicine.medical_specialtyAdenosinePrasugrel030204 cardiovascular system & hematologySTEMI03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineP2Y12Internal medicinemedicineHumans030212 general & internal medicineAgedbusiness.industryMiddle AgedMagnetic Resonance ImagingMicrovesselsPurinergic P2Y Receptor AntagonistsCardiologyST Elevation Myocardial InfarctionMVOFemaleCardiology and Cardiovascular MedicinebusinessPrasugrelPrasugrel HydrochlorideTicagrelorPlatelet Aggregation InhibitorsMRImedicine.drugInternational Journal of Cardiology
researchProduct

Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.

2015

BACKGROUND A retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs). OBJECTIVES The authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs. METHODS Follow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization. RESULTS The mean patient age was 62.0 +/- 10.4 years; 88.5% were men. Procedural and clinical…

MaleTime FactorsIncidenceMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareHospitalsEuropeElectrocardiographyPercutaneous Coronary InterventionPostoperative ComplicationsTreatment OutcomeCoronary Occlusionchronic total occlusionsJ-CTO scoreChronic DiseaseHumansretrograde PCI revascularizationFemaleHospital MortalityProspective StudiesRegistrieschronic total occlusionFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study

2015

Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this…

MaleTime FactorsPercutaneousKnee Jointmedicine.medical_treatmentDentistryFracture Fixation InternalFracture FixationTibial plateau fracture Surgical treatment Bone graft Ceramic injectable biphasic bone substitute Clinical and radiographic outcomeFracture fixationTibial plateau fractureOrthopedics and Sports MedicineProspective StudiesTomographyFracture HealingSurgical treatmentBone TransplantationMiddle AgedCombined Modality TherapyBiomechanical PhenomenaX-Ray ComputedDrug CombinationsTreatment Outcomemedicine.anatomical_structureSettore MED/03FemaleResearch ArticleAdultmedicine.medical_specialtyBone healingCalcium SulfateInjectionsRheumatologyClinical and radiographic outcomeTibial plateau fracturemedicineBone graftHumansInternal fixationTibiaTibiabusiness.industryRecovery of Functionmedicine.diseaseInternalSurgeryTibial FracturesDurapatiteCeramic injectable biphasic bone substituteIrregular boneBone SubstitutesOrthopedic surgeryAdult; Biomechanical Phenomena; Bone Substitutes; Bone Transplantation; Calcium Sulfate; Combined Modality Therapy; Drug Combinations; Durapatite; Female; Follow-Up Studies; Fracture Fixation Internal; Fracture Healing; Humans; Injections; Knee Joint; Male; Middle Aged; Prospective Studies; Recovery of Function; Tibia; Tibial Fractures; Time Factors; Tomography X-Ray Computed; Treatment OutcomeTomography X-Ray ComputedbusinessFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

2020

Objective Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI >= 75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI >= 75 years. Methods We included 979 patients with STEMI >= 75 years, from the ATencion HOspitalaria del Sindrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-P…

MaleTime FactorsPercutaneoussistema de registrosmedicine.medical_treatmenthumanosComorbidityCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regression0302 clinical medicineRecurrenceRisk Factorsevaluación de riesgosST segmentRegistries1506030212 general & internal medicineMyocardial infarctionAged 80 and overancianocoronary intervention (PCI)resultado del tratamientoCardiogenic shockAge FactorsShockstemiTreatment Outcomesurgical procedures operativeCardiologyFemaleAcute coronary syndromeCardiology and Cardiovascular MedicineStemiAcute coronary syndromemedicine.medical_specialtyShock CardiogenicPulmonary EdemaRisk Assessmentacute coronary syndromeedema pulmonar03 medical and health sciencesfactores de tiempoPercutaneous Coronary Interventionchoquecirugía coronaria percutáneaInternal medicinemedicinefactores de riesgoHumanscardiovascular diseasesAgedCoronary intervention (PCI)business.industryPercutaneous coronary interventionmedicine.diseaseSpainPropensity score matchingST Elevation Myocardial InfarctionbusinessrecurrenciaOpen Heart
researchProduct